A study reported that, as novel MALT1 inhibitors, β-lapachone analogs exhibited potent antiproliferative activity and inhibited the cleavage of CYLD mediated MALT1; this may be a promising therapeutic target for the treatment of aggressive subtype of diffuse large B-cell lymphoma [27]. Here, CYLD is linked to diffuse large B-cell lymphoma.